4 Drugs Considered Riskier Than Beneficial by Prescrire
“`html
Medications to Avoid: 2026 “Prescribe” Blacklist Update
What Happened: New Additions to the Blacklist
According to the review Prescribe, it would be better to avoid certain medications, even those you may have in your medicine cabinet. The 2026 edition of its annual report highlights four new treatments, in addition to 104 already identified, deemed ineffective or dangerous. The independent publication aims to guide patients and caregivers towards safer choices to avoid disproportionate harm.
The new entrants to the blacklist are not unknown. They include fezolintant (Veosa), prescribed to relieve hot flashes of menopause, and gefapixant (harrow), intended to treat chronic cough. The primary concern is that the adverse effects of these medications are too frequent or too serious compared to the expected benefits.
The 2026 Blacklist: A Closer look
in 2026,andexanet alfa,chondroitin,fezolintant,and gefapixant were added to the blacklist. All share an unfavorable benefit-risk balance, according to the publication.
| Medication | Indication | Reported Risks |
|---|---|---|
| Andexanet alfa | Reversal of anticoagulant effects (hospital use) | Increased risk of thrombosis |
| Chondroitin | Osteoarthritis | Allergic reactions |
| Fezolintant (Veosa) | Menopausal hot flashes | Hepatic risks, digestive disorders, neuropsychiatric effects |
| Gefapixant (Harrow) | Chronic cough | Taste disorders, respiratory infections, urinary problems |
Detailed Risk Profiles
Andexanet Alfa
Used in hospitals to reverse the effects of anticoagulants, andexanet alfa has been linked to an increased risk of thrombosis, potentially negating the benefits of reversal in certain cases.
Chondroitin
While commonly prescribed for osteoarthritis, chondroitin can cause allergic reactions in some individuals. The efficacy of chondroitin for osteoarthritis is also a subject of ongoing debate.
Fezolintant (Veosa)
This non-hormonal treatment for menopausal hot flashes carries notable risks, including potential liver damage, digestive issues, and neuropsychiatric effects. These risks may outweigh the benefits for manny patients.
Gefapixant (Harrow)
Often prescribed for chronic cough, gefapixant is associated with very common taste disorders, as well as respiratory infections and urinary problems. The impact on quality of life due to taste disturbances is a significant concern.
What Does This Mean for Patients?
The Prescribe report underscores the importance of informed decision-making in healthcare. Patients should actively discuss their medications with their healthcare providers, weighing the potential benefits against the known risks. Don’t hesitate to ask questions and seek second opinions.
Its crucial to remember that this report doesn’t necessarily